SCHEMBL6328965

SCHEMBL6328965

Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(-c2ccccc2)c1S(C)(=O)=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.58
PDGFRB P09619 4/20 0.56
FLT3 P36888 7/20 0.54
ALK Q9UM73 7/20 0.54
RET P07949 5/20 0.54
FGFR1 P11362 5/20 0.54
FLT1 P17948 4/20 0.54
CSF1R P07333 3/20 0.54
FGFR3 P22607 3/20 0.54
FLT4 P35916 3/20 0.54
AURKA O14965 3/20 0.54
MAP4K2 Q12851 3/20 0.54
STK3 Q13188 3/20 0.54
AURKB Q96GD4 3/20 0.54
SRC P12931 2/20 0.54
MAPK1 P28482 2/20 0.54
ZAP70 P43403 2/20 0.54
PLK4 O00444 2/20 0.54
PDPK1 O15530 2/20 0.54
JAK2 O60674 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326979 0.89 ALK (0.50) KDRPDGFRBFLT3ALKRET
SCHEMBL6328615 0.88 KDR (0.49) KDRPDGFRBFLT3ALKRET
SCHEMBL6326803 0.87 RET (0.56) KDRPDGFRBRETFGFR1ZAP70
SCHEMBL6329255 0.87 KDR (0.49) KDRPDGFRBFLT3ALKRET
SCHEMBL6327010 0.87 ALK (0.59) KDRPDGFRBFLT3ALKRET
SCHEMBL6328765 0.87 RET (0.56) KDRPDGFRBALKRETFGFR1
SCHEMBL6333695 0.85 PDGFRB (0.55) KDRPDGFRBFLT3RETFGFR1
SCHEMBL6327563 0.85 RET (0.58) KDRPDGFRBFLT3RETFGFR1
SCHEMBL6330154 0.84 KDR (0.55) KDRPDGFRBFLT3ALKFGFR1
SCHEMBL6330995 0.83 ALK (0.43) KDRPDGFRBFLT3ALKRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032871-A1 Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors SUGEN, INC. 2005-02-10 US claimed
US-20050032871-A1 Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors SUGEN, INC. 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032871-A1 Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors MAP3K20, CDK20, STK10 KDR 974/4885PDGFRB 472/4885FLT3 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.